Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod

CNS Neurosci Ther. 2018 Oct;24(10):984-986. doi: 10.1111/cns.12992. Epub 2018 Jun 13.

Authors

Maria Eleftheria Evangelopoulos^{1

2}, Andrei Miclea², Lisa Schrewe², Myriam Briner², Anke Salmen², Britta Engelhardt³, Andrea Huwiler⁴, Andrew Chan², Robert Hoepner²

Affiliations

¹ Department of Neurology, Eginition University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Neurology, Bern University Hospital and University of Bern, Switzerland.
³ Theodor Kocher Institute, University of Bern, Bern, Switzerland.
⁴ Institute of Pharmacology, University of Bern, Bern, Switzerland.

No abstract available

Keywords: FTY; Disease activity; Disease reactivation; Gilenya; MS relapse.

Publication types

Letter

MeSH terms

Adult
Female
Fingolimod Hydrochloride / adverse effects*
Humans
Immunosuppressive Agents / adverse effects*
Male
Middle Aged
Multiple Sclerosis / drug therapy*
Recurrence
Retrospective Studies
Substance Withdrawal Syndrome / diagnosis*
Substance Withdrawal Syndrome / etiology*

Substances

Immunosuppressive Agents
Fingolimod Hydrochloride